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Abstract 
Background: Birdshot chorioretinopathy is a chronic bilateral inflammatory disease of unknown etiology character-
ized by bilateral retinal vasculitis, mild to moderate vitritis, retinal vascular leakage, cystoid macular edema (CME), and 
typical “birdshot” chorioretinal lesions. Typically, patients with birdshot chorioretinopathy are treated with systemic 
immunosuppressive and/or corticosteroid therapy in an effort to minimize loss of vision. Spectral-domain OCT (SD-
OCT) has shown regional or generalized photoreceptor loss in addition to both retinal as well as choroidal thinning 
in these patients. The present study describes anatomical changes of the retina and alterations in choroidal thickness 
and vasculature on sequential spectral-domain optical coherence tomography (SD-OCT) in 4 patients with birdshot 
chorioretinopathy treated with local corticosteroids.
Methods: A retrospective observational case series identified 4 consecutive patients (8 eyes) at New England Eye 
Center, Boston diagnosed with birdshot chorioretinopathy according to the research criteria of the international 
consensus conference that were managed by a single retina specialist and treated exclusively with local corticosteroid 
therapy (intravitreal/sub-tenon injections) without systemic immunosuppression. All patients underwent longitudinal 
SD-OCT imaging with both the 512 × 128 cube scan and the 1-line raster protocol. A chart review was performed to 
review the visual response to treatment. Two independent observers analyzed sequential SD-OCT images for retinal 
parameters such as occurrence of CME at any time during the course of disease, presence of retinal thinning and pres-
ence of hyper-reflective foci within the retina, and choroidal parameters including its thickness and its vasculature.
Results: Mean age of the patients at diagnosis was 47 years (26–60 years). Mean duration of follow-up was 
96 months. All patients were HLA-A29 positive. Visual acuity remained stable in 75 % of eyes, 63 % eyes had central 
retinal thinning, 75 % eyes had hyper reflective foci within the retina and 75 % eyes had CME during follow-up. Mean 
total sub-foveal choroidal thickness of all 8 eyes at the time of the last SD-OCT was significantly lower than at initial 
SD-OCT (p = 0.03).
Conclusions: This case series suggests that treatment with local corticosteroids may have good visual outcome 
despite retinal and choroidal thinning. Future longitudinal studies are necessary to further determine the benefits of 
local corticosteroid therapy.
© 2016 Gobuty et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
Birdshot chorioretinopathy is a chronic bilateral inflam-
matory disease of unknown etiology that is strongly asso-
ciated with HLA-A29 genotype [1]. It is characterized 
by bilateral retinal vasculitis, mild to moderate vitritis, 
retinal vascular leakage, cystoid macular edema (CME), 
and typical “birdshot” chorioretinal lesions. The latter are 
characterized as multiple cream-yellow colored hypo-
pigmented choroidal infiltrates [1–4]. Overtime, vascular 
attenuation and atrophy of the retinal pigment epithelium 
(RPE), photoreceptors, choroid and optic nerve develop, 
that can significantly compromise vision [1–4].
A progressive loss of vision occurs in patients with 
birdshot chorioretinopathy over 2–3 decades [2, 4, 5]. 
Disease course is generally monitored with changes in 
visual acuity over time, cellular reaction within the ante-
rior chamber and vitreous, leakage of the retinal vascula-
ture and the appearance of the hallmark birdshot lesions. 
Visual acuity alone has not been shown to significantly 
correlate with clinical inflammation and therefore does 
not fully reflect disease severity in birdshot chorioretin-
opathy [6]. Fluorescein angiography and indocyanine 
green angiography have been utilized to visualize the 
vascular architecture in these patients and monitor the 
extent of vascular leakage as a proxy for disease activ-
ity [7, 8]. In addition, optical coherence tomography 
(OCT), visual fields and electroretinography (ERG) can 
also be used to monitor disease activity [9–12]. Using 
spectral-domain OCT (SD-OCT) regional or generalized 
photoreceptor loss in addition to both retinal as well as 
choroidal thinning has been observed [3]. A recent study 
showed that OCT is a valuable tool to quantify the retinal 
degeneration in birdshot chorioretinopathy patients [13]. 
More recently, optical coherence tomography angiog-
raphy (OCTA) has demonstrated the absence of chorio-
capillaris beneath the disrupted RPE within the birdshot 
lesions and within the retinal vasculature telangiectatic 
vessels and dilated capillaries with increased intercapil-
lary space were identified [14].
Typically, patients with birdshot chorioretinopathy are 
treated with systemic immunosuppressive and/or corti-
costeroid therapy in an effort to minimize loss of vision 
[5, 15–20]. Of late, intravitreal sustained release devices 
show improved vision and decreased inflammation in 
these cases [4, 21]. The present case series aims to study 
the visual outcome and anatomical changes such as the 
morphological features of the retina and alterations 
in choroidal thickness and vasculature on sequential 
SD-OCT over time in 4 patients with birdshot chori-
oretinopathy treated with local corticosteroid therapy.
Methods
Patients
A retrospective observational case series identified 4 
consecutive patients (8 eyes) at the New England Eye 
Center, Tufts University School of Medicine, Boston 
diagnosed with birdshot chorioretinopathy according to 
the research criteria of the international consensus con-
ference that were managed by a single retina specialist 
(JSD) and treated exclusively with local corticosteroid 
therapy (intravitreal/sub-tenon injections) without sys-
temic immunosuppression [22]. All patients had bilateral 
disease and had at least 3 peripapillary birdshot lesions 
with anterior segment and/or vitreal inflammation. HLA 
typing for HLA-A29, fluorescein angiography and indo-
cyanine green angiography for presence of vascular leak-
age, and OCT imaging to detect cystoid macular edema 
(CME) were performed to support the diagnosis. In all 
cases, visual fields were performed to follow the progres-
sion of disease. Ancillary testing ruled out other causes of 
multifocal choroidal lesions when indicated. Retrospec-
tive chart review identified the disease course and the 
visual response to the administered treatment. Sequential 
SD-OCT images were analyzed to determine the anatom-
ical changes over time. This study received approval from 
the Institutional Review Board. The research adhered to 
the tenets of the Declaration of Helsinki and complied 
with the Health Insurance Portability and Accountability 
Act of 1996. Informed consent was considered exempt 
for this study due to its retrospective design by the Insti-
tutional Review Board.
SD‑OCT imaging and analysis of the retinal and choroidal 
changes
All patients underwent longitudinal SD-OCT imaging 
with both the 512 × 128 cube scan and the 1-line raster 
protocol on Cirrus HD-OCT (Carl Zeiss Meditec Inc, 
Dublin, California, USA). The 1-line raster protocol is a 
6-mm line scan that acquires 20 frames at the same reti-
nal location that are then averaged together to increase 
the signal-to-noise ratio. The enhanced depth imaging 
(EDI) protocol could not be employed, as it was not avail-
able on the Cirrus device at the time most of these scans 
were performed.
Two independent OCT raters (MA and SPR) expe-
rienced in analyzing SD-OCT images studied the 
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morphology of the retina and choroid on sequential 
SD-OCT images in all patients [23]. The retinal param-
eters analyzed included (1) occurrence of CME at any 
time during the course of disease, (2) presence of retinal 
thinning and (3) presence of hyper-reflective foci within 
the retina. The subfoveal total choroidal thickness and 
the subfoveal large choroidal vessel layer thickness were 
measured using previously described methods in all eyes 
[24–27]. Medium choroidal vessel layer/choriocapillaris 
layer thickness was calculated by subtracting the subfo-
veal large choroidal vessel layer thickness from the subfo-
veal total choroidal thickness [24–27].
Statistical analysis
All data was expressed as mean ±  standard error of the 
mean (SEM). The differences in the total choroidal thick-
ness and thickness of the individual choroidal vascular 
layers from an initial SD-OCT to the recent most SD-
OCT image (final SD-OCT) were analyzed using a paired 
t-test. Pearson correlation was used to determine correla-
tion of central retinal thickness with the subfoveal total 
choroidal thickness and the subfoveal large choroidal 
vessel layer thickness. A 95 % confidence interval and a 
5 % level of significance were adopted; therefore, results 




Mean age of the patients at diagnosis was 47 years (26–
60 years). Mean duration of follow-up was 96 months. All 
patients were HLA-A29 positive.
Patient 1 was diagnosed with birdshot chorioretinopa-
thy at age 54. At initial presentation, his best-corrected 
visual acuity (BCVA) was 20/50 in the right and 20/30 in 
the left eye. OCT imaging showed no evidence of CME. 
Three years after presentation, he developed an extrafo-
veal choroidal neovascularization (CNV) in the left eye 
that was treated with focal laser therapy. He later devel-
oped CME bilaterally that was treated with bilateral 
intravitreal corticosteroid (triamcinolone 4  mg) injec-
tions every 6 months. A retinal detachment developed in 
his right eye that was treated with pneumatic retinopexy. 
At his recent follow-up in 2015, 11 years after his initial 
presentation, the patient had received 11 and 9 triamci-
nolone injections in his right and left eye respectively. He 
remained a glaucoma suspect in both eyes and is treated 
with dorzolamide-timolol. He underwent cataract sur-
gery in 2009 and 2014. His BCVA was 20/50 in the right 
and 20/30 in the left eye, SD-OCT imaging showed reti-
nal thinning without CME and visual fields remained rel-
atively stable (Fig. 1).
Patient 2 was diagnosed with birdshot chorioretin-
opathy at age 48. On presentation, BCVA was 20/30 in 
the right and 20/20 in the left eye. OCT showed CME 
in the right eye that was treated with a single subtenon 
triamcinolone injection (Fig. 2). The CME resolved with 
treatment, however, he developed secondary elevated 
intraocular pressure. At his recent follow up in 2013, his 
intraocular pressure was well controlled (11 bilaterally) 
on dorzolamide-timolol twice a day. BCVA in the right 
eye was 20/50 and that in the left eye was 20/30 and OCT 
showed no CME bilaterally.
Patient 3 (sister of patient 2, see above) was diagnosed 
with birdshot chorioretinopathy at another institution in 
1993 at age 34 where she was treated with cyclosporine 
300 mg daily. She first presented to the New England Eye 
Center in 1999 for a second opinion. At that time, she 
had been off immunosuppressive medications for 2 years 
and her BCVA was 20/70 in the right and 20/60 in the left 
eye. OCT showed prominent CME and cystic changes 
bilaterally. Treatment was deferred 3 years for pregnancy. 
Three years later, she was treated with intravitreal triam-
cinolone injections bilaterally. She received a total of four 
injections in her right eye and five injections in her left 
eye for recurring CME and inflammation over the next 
13  years. She developed intraocular hypertension that 
has been managed with dorzolamide-timolol. She under-
went cataract surgery in the right eye in 2010 and in the 
left eye in 2003. At her recent follow-up in 2015, the 
BCVA was 20/40 in the right and 20/200 in the left eye 
and OCT showed no evidence of CME. Her VF showed 
dense arcuate scotomas bilaterally.
Patient 4 was diagnosed with birdshot chorioretinopa-
thy 28 years ago at another institution. She first presented 
to the New England Eye Center at age 54 for a second 
opinion. At presentation, her BCVA was 20/40 in the 
right and 20/200 in the left eye. OCT imaging showed 
minimal CME in the left eye treated with intravitreal tri-
amcinolone injection. She has received two intravitreal 
triamcinolone injection in the left and one in her right 
eye. She underwent cataract surgery in her right eye in 
2013 and in her left eye in 2010. At her recent follow 
up in 2015, her visual fields remained stable with mild 
improvement in the right eye and on OCT thinning was 
noted bilaterally. The BCVA was 20/40 in the right and 
20/70 in the left eye and OCT showed no evidence of 
CME.
SD‑OCT analysis of the retinal and choroidal changes
The morphological features of the retina analyzed on SD-
OCT are described in Table 1. The demographic charac-
teristics, treatment, and visual outcomes of patients are 
presented in Table 2. Choroidal thickness and vasculature 
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Fig. 1 Initial and final visual field exams for all patients except patient 2 who only had an initial visual field exam. Patient 1 remained relatively 
stable. Patient 3 had progression showing dense arcuate scotomas bilaterally. Patient 4 showed mild improvement in the right eye
Fig. 2 Sequential SD-OCT images of the right eye from patient 2 showing response to treatment with intravitreal triamcinolone acetate. Complete 
resolution of CME following an intravitreal triamcinolone acetate injection is seen in this patient. SD-OCT spectral-domain optical coherence tomog-
raphy, CME cystoid macular edema, mo months, IVK intravitreal triamcinolone acetate
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changes at initial and final SD-OCT are charted in Fig. 3. 
The mean total sub-foveal choroidal thickness of the 
8 eyes at the time of the last SD-OCT was significantly 
lower than at the initial SD-OCT (p = 0.03). There was 
no correlation of the mean central retinal thickness with 
the sub-foveal total choroidal thickness and the sub-
foveal large choroidal vessel layer thickness (p = 0.83 and 
p = 0.10 respectively).
Discussion
The present case series describes the visual response 
in consecutive patients with birdshot chorioretinopa-
thy treated with local corticosteroid therapy. It further 
describes the retinal morphology and alterations in total 
choroidal thickness and thickness of the individual cho-
roidal vascular layers on sequential SD-OCT in these 
patients.
Traditionally, patients with birdshot chorioretinopa-
thy are treated with systemic immunosuppressive medi-
cations and/or systemic corticosteroids [12, 15–20]. 
Regional or systemic corticosteroids combined with 
cyclosporine or replaced from the outset by immunosup-
pressive therapy reduce vascular leakage and improve 
vision in these patients [15–20]. The use of immunomod-
ulatory treatment (IMT) is supported by recent evidence 
suggesting that patients in remission without IMT may 
have subclinical inflammation [28]. Since birdshot cho-
rioretinopathy has not been associated with systemic 
manifestations, intraocular drug delivery is an alternative 
therapeutic option. A study showed that implantation of 
a fluocinolone acetonide-containing intraocular device 
in patients with birdshot chorioretinopathy improves 
vision and reduces inflammation [4]. While eliminat-
ing the need for systemic immunosuppressive therapy, 
this study showed an increase in incidence of corticos-
teroid-induced glaucoma with 100  % of patients experi-
encing intraocular pressure greater than 25  mmHg and 
all 19 phakic eyes eventually requiring cataract surgery 
[4]. The present study suggests that local corticosteroid 
therapy alone administered as needed for CME or signs 
of intraocular inflammation may be a useful treatment 
option for the management of birdshot chorioretinopa-
thy. While the local side effects such as glaucoma and cat-
aract formation are expected in some eyes owing to the 
need of multiple injections, the systemic side effect pro-
file is minimal. In this study, the visual acuity remained 
stable in 6 of 8 (75 %) eyes and visual fields (Fig. 1) dis-
played relative stability with mild progression in 2 of 6 
eyes (33 %) over a mean follow up period of 96 months. 
Table 1 Morphological features of  the retina analyzed 











Patient 1 1/2 2/2 2/2
Patient 2 0/2 0/2 1/2
Patient 3 2/2 2/2 2/2
Patient 4 2/2 2/2 1/2
Total % 62.5 75 75
Table 2 Demographic characteristics, treatment, and visual outcomes of patients with birdshot chorioretinopathy
PCL pale choroidal lesions, ERM epiretinal membrane, RD retinal detachement, CME cystoid macular edema, CNV choroidal neovascularization, VC vitreous cell, C/D 
cup to disk, IVK intravitreal triamcinolone acetate, PRP pan-retinal photocoagulation, N/A not applicable, PVD posterior vitreous detachment












1 54 yo None 20/50 OD 20/50 OD VC, ERM, RD, 
CME, PCL
VC, ERM, CME, 
PCL, CNVb
No Positive Focal laser OS, 
pneumatic 
retinopexy OD, 
IVK × 711 OD, 
IVK × 9 OS
54 yo 20/30 OS 20/30 OS
2 48 yo None 20/30 OD 20/50 OD ERM, CME, PCL, 
glaucomac
ERM, PCL Yes Positive Subtenon 
triamcinolone 
acetate OD, DC 
secondary to 
glaucoma
48 yo 20/20 OS 20/30 OS
3 34 yo Systemic 
immuno- 
suppressantsa
20/70 OD 20/40 OD ERM, CME, PCL ERM, CME, PCL Yes Positive IVK × 4 OD, 
IVK × 5 OS40 yo 20/60 OS 20/200 OS
4 26 yo None 20/40 OD 20/40 OD VC, PVD, PCL VC, PVD, CME, 
PCL
No Positive IVK × 1 OD, 
IVK × 2 OS54 yo 20/200 OS 20/70 OS
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Six of the 8 (75  %) eyes had evidence of ocular hyper-
tension and 6 of 8 (75 %) developed cataracts during the 
course of follow-up.
This study showed central retinal thinning in 5 of 8 
(62.5  %) eyes with birdshot chorioretinopathy. CME 
occurred in 6 of 8 (75 %) eyes during the course of fol-
low-up. Hyper-reflective spots within the retina were 
observed in 6 of 8 (75  %) eyes and may suggest retinal 
pigment migration and/or clumping of the photorecep-
tors over a region of the RPE and/or photoreceptor dis-
ruption [3, 30]. Interestingly, a thinning of the subfoveal 
total choroid and the individual choroidal vascular layers 
over time was observed on sequential SD-OCT images. 
Keane et al described a thinning of the medium choroidal 
vessels in some patients with birdshot chorioretinopathy 
when compared to normal subjects [3]. The present study 
suggests that the choroid thins out over time in birdshot 
chorioretinopathy and this thinning primarily involves 
the large choroidal vessel layer (Fig.  3). Furthermore, 
there was no correlation of central retinal thickness and 
subfoveal total choroidal thickness and the sub-foveal 
large choroidal vessel layer thickness in all patients. This 
is consistent with the belief that choroidal and retinal 
inflammation may occur independently in patients with 
birdshot chorioretinopathy [3]. A limitation of this study 
was the inability to perform enhanced depth imaging 
[29] scans but all eyes had a clearly visible choroidoscle-
ral interface at the subfoveal location without EDI and 
good inter observer correlation of choroidal thickness 
measurements.
Conclusions
In conclusion, the present case series describes the visual 
outcome and anatomical changes in 4 patients with bird-
shot chorioretinopathy managed by a single retina spe-
cialist (JSD) in a single setting using local corticosteroid 
therapy. It shows that local corticosteroid therapy is a val-
uable therapeutic option for treatment of birdshot chori-
oretinopathy and can eliminate and/or delay the need for 
systemic immunosuppression. While local corticosteroid 
Fig. 3 Analysis of the subfoveal total choroidal thickness and the thickness of the individual choroidal vascular layers. a Graph showing reduction 
in the subfoveal total choroidal thickness (SFCT), subfoveal large choroidal vessel layer (LVL) thickness and subfoveal medium choroidal vessel/cho-
riocapillaris layer (SVL) thickness during follow-up. The numbers represent the mean thickness values. b SD-OCT images from patient 1 showing a 
reduction in the subfoveal total choroidal thickness over a 33-month period. SD-OCT spectral-domain optical coherence tomography, mo months
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therapy is helpful at preserving visual function, it does 
not appear to prevent the retinal and choroidal changes 
that presumably occur secondary to the disease progres-
sion. Future longitudinal studies looking at a larger num-
ber of patients followed over a long time are expected 
to further determine the benefits of local corticosteroid 
therapy in this disease.
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